Advertisement

Topics

SANOFI Company Profile

09:13 EDT 22nd June 2018 | BioPortfolio

SANOFI concentrate their research efforts where the most pressing medical needs and public health issues are, bringing solutions to patients and contributing to a healthier society worldwide:

  • DIABETES
  • CANCER
  • CARDIOVASCULAR DISEASES
  • INFECTIOUS DISEASES
  • ELEDERLY PATIENTS & AGING
  • OPHTHALMOLOGY
  • RARE DISEASES &
  • MULTIPLE SCLEROSIS

R&D PORTFOLIO

At the beginning of February 2013, SANOFI had 64 projects and vaccines under clinical development including 17 in phase 3 or submitted to healthcare authorities in the R&D portfolio of Sanofi.

Since the publication of the third quarter results, on October 25, 2012, Sanofi received the following regulatory decisions:

  • The approval of Zaltrap® (aflibercept) by the European Commission in metastatic colorectal cancer that is resistant to or has progressed after an oxaliplatin-containing regimen.
  • The approval of Lyxumia® (lixisenatide) by the European Commission in type 2 diabetes and the submission to the FDA mid-December.
  • The FDA approval of Kynamro™ (mipomersen sodium, development partnership with Isis Pharmaceuticals) for the treatment of patients with Homozygous Familial Hypercholesterolemia.
  • The FDA accepted for review the supplemental biologics license application file seeking approval of Lemtrada™ (alemtuzumab, being developed in Multiple Sclerosis in collaboration with Bayer Healthcare) for the treatment of relapsing multiple sclerosis.
  • In addition, ENCORE, the second pivotal phase III trial of the investigational oral therapy, eliglustat, in Gaucher disease, met its primary efficacy endpoint of clinical stability compared to Cerezyme®.

Location

54, rue La Boétie
Paris
75008
France

Contact

Phone: +33 (0)1 53 77 40 00


News Articles [738 Associated News Articles listed on BioPortfolio]

Sanofi turns down option to develop lumasiran

Alnylam Pharmaceuticals says that Sanofi Genzyme, the biotech unit of French pharma major Sanofi has…

Zerhouni Retires, Sanofi's New R&D Chief John Reed Brings Early Research Experience From Roche

Sanofi's longtime head of R&D Elias Zerhouni will step down in July. He was a steady hand at Sanofi amid...   

Sanofi Gets U.S. Regulatory Approval For Proposed Acquisition Of Bioverativ

PARIS (dpa-AFX) - Sanofi (SNYNF, SNY) said that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the 'HSR Act'), applicable to Sanofi's proposed acqui...

Sanofi looks to trim down with divestments

Sanofi has begun part of a larger process of slimming down its business with the sales of 12 medicines. It offloaded the drugs to Charterhouse Capital Partner’s Cooper-Vemedia for €158 million, wi...

Sanofi steals in to buy Ablynx for €3.9 billion

Sanofi has leapt in to buy Ablynx for €3.9 billion ($4.85bn) outbidding an offer from Novo Nordisk which the European biotech had declined two weeks ago. For Sanofi, the acquisition comes hot on th...

Sanofi agrees to buy Bioverativ for $11.6bn

French biopharmaceutical firm Sanofi has signed a definitive agreement to purchase all outstanding shares of US-based biotechnology company Bioverativ for...Read More... The post Sanofi agrees to buy ...

Sanofi Quarterly Sales Sluggish with Focus on Integrating Bioverativ and Ablynx

Paris-based Sanofi reported mixed first-quarter revenues, with net sales down 8.7 percent to 7,898 million euros. But Sanofi Genzyme sales were up 16.2 percent, mostly the result of its new immunology...

Sanofi to Acquire Ablynx for 3.9 Billion Euros

NewsSanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies, entered into a definitive agreement under which Sanofi will offer to acquire all of the outst...

Drugs and Medications [50 Associated Drugs and Medications listed on BioPortfolio]

Nilandron [sanofi-aventis U.S. LLC]

NILANDRON (nilutamide)Tablets

Allegra d 12 hour allergy and congestion [Rebel Distributors Corp]

Allegra-D 12 Hour Allergy and Congestion

Allegra d 12 hour allergy and congestion [Chattem, Inc.]

Allegra-D 12 Hour Allergy and Congestion

Hiprex(methenamine hippurate tablets usp) [sanofi-aventis U.S. LLC]

HIPREX(methenamine hippurate tablets USP)

Taxotere [sanofi-aventis U.S. LLC]

These highlights do not include all the information needed to use TAXOTERE safely and effectively. See full prescribing information for TAXOTERE.  TAXOTERE (docetaxel) Injection Concentrate, Intraven...

PubMed Articles [8 Associated PubMed Articles listed on BioPortfolio]

C-621/15 - W And Others v Sanofi Pasteur: An Example of Judicial Distortion and Indifference to Science.

This case commentary examines the CJEU's recent decision in C-621/15 W and Others v Sanofi Pasteur MSD SNC [2017] ECR I. This commentary critically examines the decision through the lens of the cultur...

Intravitreal Ziv-Aflibercept for Diabetic Macular Edema: 48-Week Outcomes.

To study the safety and efficacy of intravitreal injections of ziv-aflibercept (IVI-ZA) (Zaltrap; Sanofi-Aventis and Regeneron Pharmaceuticals, Tarrytown, NY) during a period of 48 weeks in patients w...

Letter--Incorporating Real-World Evidence and Patient Value Criteria into Value-Based Frameworks for Relapsed/Refractory Multiple Myeloma.

Orlowski has received research funding from Amgen, BioTheryX, Bristol-Myers Squibb, Celgene Corporation, and Takeda Pharmaceuticals; honoraria from Amgen, Bristol-Myers Squibb, Celgene Corporation, Ja...

Imidazopyrazinones (IPYs): non-quinolone bacterial topoisomerase inhibitors showing partial cross-resistance with quinolones.

In our quest for new antibiotics able to address the growing threat of multi-drug resistant infections caused by Gram-negative bacteria, we have investigated an unprecedented series of non-quinolone b...

Plant-expressed Fc-fusion protein tetravalent dengue vaccine with inherent adjuvant properties.

Dengue is a major global disease requiring improved treatment and prevention strategies. The recently licensed Sanofi-Pasteur Denvaxia vaccine does not protect children under the age of nine and addit...

Clinical Trials [69 Associated Clinical Trials listed on BioPortfolio]

Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America

Primary objectives: - To describe the immune response to each dengue serotype before and after each vaccination with sanofi pasteur's CYD dengue vaccine. - To evaluate t...

A Bioequivalence Study Comparing Camoquin® Suspension (Pfizer) To Flavoquine® Tablets (Sanofi Aventis) In Healthy Subjects

The purpose of this study is to determine bioequivalence of amodiaquine suspension ( Pfizer) and the WHO approved reference product Flavoquine® tablet ( Sanofi Aventis).

Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand

The present clinical study will assess the immunogenicity and reactogenicity of Sanofi Pasteur's DTacP-IPV// PRP~T combined vaccine (Pentavac™ or Pentaxim™) as a three-dose primary vac...

Sanofi Pasteur Quadrivalent Influenza Vaccine (QIV) Pregnancy Registry

The Sanofi Pasteur Quadrivalent Influenza Vaccine (QIV) Pregnancy Registry will be a prospectively recruited pregnancy surveillance program designed to collect and analyze information on v...

Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects

This trial will evaluate the use of a tetravalent vaccine against dengue. Primary objectives: - To describe the immune response to dengue before and after each vaccination with ...

Companies [62 Associated Companies listed on BioPortfolio]

sanofi-aventis U.S.

Sanofi-aventis U.S. is an affiliate of sanofi-aventis, a leading global pharmaceutical company that discovers, develops and distributes therapeutic solutions to help improve the lives of patients. San...

Bristol-Myers Squibb & Sanofi-aventis

Sanofi-aventis U.S. is an affiliate of sanofi-aventis, a leading global pharmaceutical company that discovers, develops and distributes therapeutic solutions to help improve the l...

Sanofi Aventis Groupe

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SA...

Sanofi Pharmaceuticals Incorporated

Sanofi Pharmaceuticals are the U.S. subsidiary of Sanofi-Synthelabo, the global healthcare company. With annual sales in excess of $5.6 billion and 30,000 employees in more than 100 countries, Sanofi-...

Sanofi Pasteur MSD AG

Sanofi Pasteur MSD is the only European company dedicated exclusively to vaccines and was founded in 1994, as a joint venture between Sanofi Pasteur and Merck and Co. Inc.Sanofi Pasteur MSD develops v...

More Information about "SANOFI" on BioPortfolio

We have published hundreds of SANOFI news stories on BioPortfolio along with dozens of SANOFI Clinical Trials and PubMed Articles about SANOFI for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of SANOFI Companies in our database. You can also find out about relevant SANOFI Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...


Corporate Database Quicklinks



Searches Linking to this Company Record